Introduction
============

Overview
--------

Dysfunction of the hypothalamic--pituitary--adrenal (HPA) axis has long been implicated in the pathogenesis and etiology of severe psychiatric illness. Studies have found evidence of reduced glucocorticoid receptor **(**GR) mRNA expression in post-mortem brain tissue samples from patients with mood disorders and psychosis ([@b38-ndt-2-33]; [@b81-ndt-2-33]; [@b44-ndt-2-33]). Many antidepressant drugs increase GR binding and/or number in brain tissue, suggesting that GR regulation may be one aspect of the therapeutic mechanism of action of antidepressants (and mood stabilizers), and the ability of a drug to regulate GR number may be a good predictor of therapeutic efficacy in patients with hypercortisolemia ([@b48-ndt-2-33]). No drugs primarily or preferentially target the GR for use in psychiatry, although several are at present being examined for this purpose. The present review examines the current literature and proof-of-concept evidence for the clinical utility of GR antagonists (specifically mifepristone) in mood disorders and psychosis.

Search strategy
---------------

In order to include other antiglucocorticoid agents that specifically target the GR, the terms ("mifepristone" or "RU 486" or "RU 38486" or "ORG 34850"' or "ORG 34116" or "ORG 34517") were used in the initial search and combined with the terms ("mood disorders" or "psychosis" or "depression" or "bipolar disorder" or "schizophrenia"). The following databases were searched electronically: EMBASE (1980 to present), Medline (1966 to present), CINAHL (1982 to present), PsycINFO (1887 to present), and ISI Web of Science (1981 to present). Citation lists of relevant studies and reviews were checked for other relevant trials.

Background
==========

The hypothalamic--pituitary--adrenal (HPA) axis
-----------------------------------------------

One of the major hormonal systems activated during stress is the HPA axis. Neurones in the paraventricular nucleus (PVN) of the hypothalamus secrete corticotrophin-releasing hormone (CRH) which is transported via the hypothalamo-pituitary portal circulation to the anterior pituitary where adrenocorticotropic hormone (ACTH) is secreted through stimulation of pituitary corticotrophs. ACTH then enters the peripheral circulation and stimulates the adrenal cortex to secrete glucocorticoids: corticosterone in rats, and cortisol in humans.

Cortisol is essential for life. It is involved in the maintenance of glucose production from protein, facilitates fat metabolism, supports responsiveness of the vascular tree, modulates central nervous system function, and profoundly affects the immune system ([@b7-ndt-2-33]). Importantly, it is a major regulator of the physiological stress response, through a negative feedback mechanism via corticosteroid receptors. Two distinct corticosteroid receptor subtypes have been identified: the mineralocorticoid receptor (MR; Type I) and the glucocorticoid receptor (GR; Type II). Both receptor types have been implicated in mediating glucocorticoid feedback ([@b66-ndt-2-33]), but there are several differences in the distribution, occupancy, and binding properties of the two receptors that affect their physiological role.

The MR is highly expressed in the limbic system whereas the GR is ubiquitous, being present in both subcortical and cortical structures, with a preferential distribution in the prefrontal cortex ([@b61-ndt-2-33]). Glucocorticoids bind to the MR with 6--10 times higher affinity than to GR ([@b14-ndt-2-33]). Consequently, at basal levels near complete occupation (\~90%) of MRs occurs. GRs, however, are little occupied at this point (\~10%), and only during times of high cortisol secretion, such as the circadian peak or during stress, do MRs become saturated and GR occupancy increases (to \~67%--74%) ([@b66-ndt-2-33]). GR function is therefore critical in the regulation of the HPA axis at times of glucocorticoid excess and it is now recognized that disruption of this self-regulating system may be a major factor in the pathophysiology of mood disorders and psychosis.

The HPA axis in mood disorders and psychosis
--------------------------------------------

The first observations of an elevation in basal cortisol levels in patients with depression were made almost half a century ago by Board and colleagues, and these observations have been repeatedly replicated ([@b8-ndt-2-33]; [@b26-ndt-2-33]). It should be noted that the extent of HPA axis dysfunction differs by severity and subtype of depression. For example, a recent study found no evidence of hypercortisolism in women with major depression from a community-based setting ([@b77-ndt-2-33]), while pronounced HPA axis dysfunction has been described in depressed subjects with psychotic features ([@b65-ndt-2-33]). The presence of psychosis may be related to hypercortisolism independently of mood symptoms ([@b12-ndt-2-33]). Hypercortisolism has also been recognized in symptomatic schizophrenic patients ([@b67-ndt-2-33]; [@b69-ndt-2-33]).

Improvements in the methodology utilized has overcome some of the complexities surrounding the profiling of HPA axis dysfunction, revealing alterations in the diurnal pattern of cortisol secretion in depression ([@b16-ndt-2-33]; [@b65-ndt-2-33]), while employing less precise techniques such as total 24-hour cortisol output can fail to detect dysfunction ([@b9-ndt-2-33]). Similarly, the measurement of the molar ratio of cortisol to other adrenal steroids can reveal differences -- in the absence of hypercortisolism per se -- in moderately depressed, non-psychotic outpatients ([@b82-ndt-2-33]). The most sensitive tests of HPA axis function, however, are "activating" tests, whereby neuroendocrine responses are measured following pharmacological challenge. These are preferred not only because of their increased sensitivity, but because they elucidate functional changes in the HPA axis at the receptor level.

The GR agonist dexamethasone has been used widely to examine HPA axis negative feedback integrity ([@b68-ndt-2-33]). An abnormal (nonsuppressed) cortisol response to dexamethasone administration has been described in schizophrenia ([@b11-ndt-2-33]; [@b50-ndt-2-33]) (but also see [@b32-ndt-2-33]) and mood disorders ([@b68-ndt-2-33]), and may be exacerbated by psychotic features ([@b18-ndt-2-33]). The combined dexamethasone--corticotrophin-releasing hormone (dex--CRH) test is also abnormal in bipolar patients during relapse and recovery ([@b72-ndt-2-33]; [@b70-ndt-2-33]; [@b80-ndt-2-33]). Furthermore, GR abnormalities have been observed in post-mortem studies which show evidence of reduced GR mRNA expression in post-mortem brain tissue samples from patients with bipolar disorder and schizophrenia ([@b38-ndt-2-33]; [@b81-ndt-2-33]; [@b44-ndt-2-33]).

Consequences of HPA axis dysregulation and implications for treatment
---------------------------------------------------------------------

Pronounced neurocognitive dysfunction is frequently described in mood disorder ([@b63-ndt-2-33]; [@b78-ndt-2-33]); this may be worse in patients with psychotic features ([@b21-ndt-2-33]). In schizophrenia, the symptomatic clinical profile of the illness is complex and diverse, but neurocognitive impairment is consistently reported and some authors have argued that such impairments may be the cardinal feature of the illness ([@b19-ndt-2-33]).

Elevated levels of corticosteroids are known to impair learning and memory. This has been demonstrated by acute ([@b45-ndt-2-33]; [@b49-ndt-2-33]) and subchronic ([@b84-ndt-2-33]) administration of exogenous corticosteroids in healthy volunteers and in conditions associated with a chronic elevation of endogenous cortisol levels, for example Cushing's disease ([@b76-ndt-2-33]; [@b23-ndt-2-33]), which is also associated with a high incidence of depression that notably resolves with correction of the hypercortisolemia ([@b17-ndt-2-33]). Patients receiving systemic corticosteroid therapy also often exhibit cognitive impairment and, in some instances, symptoms of (hypo)mania, depression, and psychosis ([@b10-ndt-2-33]). HPA axis dysregulation therefore has been suggested to be one of the principal causes of both low mood and neurocognitive impairment, possibly through interactions with other neurotransmitter system ([@b47-ndt-2-33]; [@b64-ndt-2-33]).

The known consequences of hypercortisolemia on neurocognitive function and mood, and the central role of corticosteroid receptors in HPA axis regulation, therefore indicate a possible use for antiglucocorticoid drugs and make the GR specifically a potentially viable target for therapeutic intervention.

Mifepristone (RU-486)
=====================

Discovery and development
-------------------------

Mifepristone (or RU-486) is a synthetic steroid with both antiprogesterone and antiglucocorticoid properties. The compound is a 19-nor steroid with substitutions at positions C11 and C17 (17 beta-hydroxy-11 beta-\[4-dimethylamino phenyl\] 17 alpha-\[1-propynyl\]estra-4,9-dien-3-one) which antagonizes cortisol action competitively at the receptor level ([@b52-ndt-2-33]). It was discovered in the early 1980s by the French pharmaceutical company Roussel--Uclaf ([@b29-ndt-2-33]; [@b34-ndt-2-33]). At present it is licenced in the UK for the medical termination of pregnancy (trade name: Mifegyne^®^; marketing authorization holder: Exelgyn Laboratories, Paris, France). Mifepristone was the first antiprogestin to be developed and it has been evaluated extensively for its use as an abortifacient. The original target for the research group, however, was the discovery and development of compounds with antiglucocorticoid properties ([@b28-ndt-2-33]), and it is these properties that are of greatest interest for their application in the treatment of severe mood disorders and psychosis.

Pharmacokinetics and pharmacodynamic activity
---------------------------------------------

The pharmacokinetics of mifepristone are dose-dependent in humans ([@b1-ndt-2-33]). Due to saturation of the serum-binding capacity, high-dose mifepristone results in nonlinear kinetics, whereas lower doses show a linear pattern ([@b43-ndt-2-33]). For example, following administration of doses of 50--800 mg, after the absorption and distribution phase of approximately 4--6 hours, the serum concentration of mifepristone remains in the micromolar range for the next 24--48 hours. Within the dose range of 2--25 mg, serum concentrations of mifepristone, as well as the areas under the concentration--time curves (AUC), increase according to dose ([@b74-ndt-2-33]).

Following a single oral dose of 600 mg mifepristone, the binding equivalent is present in measurable concentrations 7 days after administration, only decreasing below assay detection limits \>7--14 days ([@b22-ndt-2-33]). In this study, the concentration of the mifepristone binding equivalent reached a peak within approximately 2 hours (doses 200--600 mg), indicating rapid absorption. Peak levels were significantly greater following the 600 mg dose (C~max~ = 12.3 μmol/L vs 200 mg: 6.30 μmol/L), while the bioavailability as assessed by the AUC was significantly greater following 600 mg dose than both 200 and 400 mg. These were not, however, directly proportional to the dose increase ([@b22-ndt-2-33]).

In contrast to mifepristone plasma concentrations, plasma concentrations of its metabolites do increase in a dose-dependent manner when larger doses are administered, so that serum metabolite concentrations are close to, or even in excess of, those of the parent compound ([@b41-ndt-2-33]). These metabolites have some antiprogestin and antiglucocorticoid properties, and therefore may mediate some of the actions of mifepristone ([@b75-ndt-2-33]).

Side effects of chronic mifepristone administration
---------------------------------------------------

Laue and colleagues reported that in healthy male normal volunteers who received mifepristone (10 mg/kg/day), 8 of 11 subjects developed generalized exanthem after 9 days. One subject developed symptoms and signs consistent with the diagnosis of adrenal insufficiency ([@b42-ndt-2-33]). For immune function, it was reported that total white blood cell counts, absolute lymphocyte, neutrophil, and eosinophil counts, erythrocyte sedimentation rate, and quantitative immunoglobulins did not change. Similarly, T-, B-, and natural killer cell subsets did not change during treatment. Furthermore, functional evaluation of lymphocyte cytotoxicity and proliferation revealed no changes.

A study using lower doses (200 mg/day for 2 to \> 31 months) in 14 patients with unresectable meningiomas reported milder side effects. Most commonly, fatigue was noted in 11 of the 14 patients ([@b27-ndt-2-33]). However, in a study of mifepristone (200 mg/day for up to 8 weeks) in chronic depression, 1 of 4 patients discontinued treatment prematurely because of the appearance of a rash ([@b51-ndt-2-33]). In patients with psychotic depression receiving mifepristone (50--1200 mg/day for 7 days), 2 of 10 patients in the 600-mg group and 1 of 9 in the 1200-mg group reported uterine cramping, while 1 of 11 patients in the 50-mg group and 1 of 9 patients in the 1200-mg group (but none in the 600-mg group) reported a rash. In both cases, this had abated 1--2 months after study completion ([@b6-ndt-2-33]).

Antiglucocorticoid effects of mifepristone
------------------------------------------

A large amount of human clinical data on the antiglucocorticoid actions of mifepristone have come from studies in Cushing's disease ([@b71-ndt-2-33]). Nieman and colleagues administered mifepristone orally at increasing doses of 5, 10, 15, and 20 mg/kg/day for a 9-week period to a patient with Cushing's syndrome due to ectopic ACTH secretion. Following treatment, the somatic features associated with Cushing's syndrome ameliorated and blood pressure normalized. Importantly, suicidal ideation and depression also resolved, and all biochemical glucocorticoid-sensitive parameters normalized ([@b52-ndt-2-33]).

Mifepristone has also been shown to rapidly reverse acute psychosis in Cushing's syndrome ([@b79-ndt-2-33]). More recently, high-dose (up to 25 mg/kg/day), long-term mifepristone administration was shown to normalize all biochemical glucocorticoid-sensitive measurements, as well as significantly reverse psychotic depression in a patient with Cushing's syndrome caused by an ACTH-secreting pituitary macroadenoma ([@b13-ndt-2-33]). Although the adrenal axis also normalized, the 18-month-long mifepristone treatment course led to the development of severe hypokalemia (attributed to excessive cortisol activation of MRs), which responded to spironolactone administration.

Use of mifepristone in mood disorders and psychosis ([Table 1](#t1-ndt-2-33){ref-type="table"})
===============================================================================================

Early work highlighted the potential for antiglucocorticoid strategies in depression. Initially the focus of studies utilizing mifepristone was on the effect on endocrine parameters ([@b37-ndt-2-33]; [@b39-ndt-2-33]). In the first open trial of mifepristone treatment of major depression, Murphy and colleagues administered mifepristone (200 mg each morning) for as long as it was tolerated, for up to 8 weeks to 4 patients with "drug-resistant" depression. Data were presented as a case-series and showed improvements of between 16% and 66% on the Hamilton Depression Rating Scale (HDRS) ([@b51-ndt-2-33]). The trial terminated, however, due to problems obtaining the trial medication (the supplier cancelled the contract).

Recent studies have renewed interest in the potential therapeutic efficacy of GR antagonists in the treatment of mood disorders and psychosis.

Psychotic depression
--------------------

In a double-blind, placebo-controlled crossover case-series in 5 patients with psychotic depression, Belanoff and colleagues found a rapid improvement in depression ratings and psychotic symptoms following 4 days' treatment with mifepristone ([@b5-ndt-2-33]). Subsequently they have replicated these findings in an open-label study in 30 psychotic depressed patients ([@b6-ndt-2-33]). Patients received mifepristone, either 50 mg/day (n = 11), 600 mg/day (n = 10), or 1200 mg/day (n = 9) for 7 days. Criteria for response were defined as a 50% reduction on the Hamilton Rating Scale for Depression-21 (HAMD-21), a 30% reduction on the Brief Psychiatric Rating Scale (BPRS), and a 50% reduction on the BPRS positive symptom subscale. Using these criteria, respectively, it was found that 18.2%, 36.4%, and 27.3% of patients responded to 50 mg/day; 50%, 70%, and 60% responded to 600 mg/day, and 33%, 66.7%, and 66.7% responded to 1200 mg/day. The results of this study also suggested that high-dose treatment (≥ 600 mg) for short periods (≤ 7 days) was the optimal method of administration.

A second trial has been carried out recently with a longer follow-up period ([@b73-ndt-2-33]). Twenty MDD patients (with psychotic features) were treated with mifepristone 200 mg 3 times daily, open-label for 6 days. All patients had been psychotropic medication-free (except lorazepam for sleep) for at least 1 week prior to baseline ratings. Significant improvements in HDRS and Clinical Global Impression (CGI) scores were observed in the group (from baseline) after 1 week and between weeks 1 and 4. This effect remained stable to follow-up at 8 weeks. BPRS scores also improved after week 4. A number of patients did not complete the trial, however, because of good clinical response (discharged and lost to follow-up) or nonresponse (alternative clinical intervention required).

Preliminary communications have also been made on the results of larger trials (n \> 200) of mifepristone in psychotic depression ([@b4-ndt-2-33]; [@b15-ndt-2-33]). These studies suggest that the effect on psychotic symptoms, particularly, may be rapid and persistent. The publication of these results is awaited and will provide clearer data on the efficacy of GR antagonists in this condition.

Bipolar disorder
----------------

We have recently completed the first proof-of-concept study on the use of GR antagonists in the treatment of bipolar depression, in a double-blind, placebo-controlled crossover design ([@b83-ndt-2-33]). We hypothesized that mifepristone (administered adjunctively to existing medication) would improve neurocognitive function and attenuate depressive symptoms in this disorder. Twenty patients, ages 18 to 65, with a diagnosis of bipolar depression (confirmed using the Structured Clinical Interview for DSM-IV; SCID \[[@b20-ndt-2-33]\]) and residual depressive symptoms were recruited. Patients' medication had been unchanged for 6 weeks prior to participation and remained so throughout the study period.

On the basis of previous research, it was predicted that the principal cognitive domains that would be most sensitive to changes in HPA axis function were working memory and verbal declarative memory. Neurocognitive tests were therefore administered to explore these domains. Following treatment with mifepristone, selective improvement in neurocognitive functioning was observed. Spatial working memory performance was significantly improved compared with placebo (19.8% improvement over placebo). Measures of verbal fluency and spatial recognition memory also significantly improved from baseline levels after mifepristone. No significant change occurred after placebo.

Beneficial effects on mood were found; HDRS scores were significantly reduced compared with baseline (mean reduction of 5.1 points) as were Montgomery--Åsberg Depression Rating Scale scores (mean reduction of 6.05 points). No significant change occurred after placebo. Furthermore, baseline cortisol output correlated positively with the percentage improvement in spatial working memory error rate following mifepristone administration.

Schizophrenia
-------------

Utilizing the same experimental design as described above ([@b83-ndt-2-33]), we have recently completed the first trial to examine the efficacy of adjunctive mifepristone administration in schizophrenia ([@b24-ndt-2-33]). In contrast to the findings on bipolar disorder, mifepristone had no significant effect on symptoms or neurocognitive functioning despite a pronounced effect on the HPA axis. There are several possible explanations for this discrepancy. As described above, mifepristone has been shown to have some positive effects on depressive symptoms in bipolar disorder as well as on psychosis in psychotic major depression. Also, the effects of mifepristone were more pronounced on neurocognitive function in bipolar patients. This may suggest that affective symptoms or affective psychosis may be modulated primarily by the HPA axis and that neurocognitive dysfunction in mood disorders is steroid-dependent and a consequence of HPA axis dysregulation, whereas in schizophrenia these may be attributable to different underlying neurobiological abnormalities.

Alternatively, it may be that the schizophrenic patients recruited in this study did not have an abnormal HPA axis at baseline. There is some evidence that the chronicity of psychotic illness directly affects the neurobiology of the HPA axis. [@b59-ndt-2-33] found that first-episode psychosis was associated with a larger pituitary volume, which was suggested to be a consequence of activation of the HPA axis. In "established" schizophrenia (such as in the population in our study), smaller pituitary volume was observed ([@b60-ndt-2-33]). Therefore, the schizophrenic patients may not respond to a GR antagonist in the same manner as patients with affective illnesses.

Other GR antagonists
--------------------

ORG 34517 was designed as a specific antiglucocorticoid to selectively target the GR. A preliminary report comparing low- and high-dose ORG 34517 administration and paroxetine found that all treatment groups showed improvements in HDRS scores over the 4-week treatment period ([@b31-ndt-2-33]). Low-dose ORG 34517 appeared to increase the speed of response, however, HDRS scores being significantly lower (from baseline) than both other treatment arms by day 10 of the trial. This effect was greater in subjects with a higher degree of HPA axis dysfunction. The proportion of subjects in full remission by the end of the trial was also significantly greater than the proportion of both the high-dose and paroxetine-treated groups (39.1% vs 20.5% and 31.0% respectively).

Mechanisms of action
====================

Corticosteroid receptor imbalance
---------------------------------

The mechanism through which mifepristone may be exerting effects on symptoms and neurocognitive function is unclear. It has been suggested that by blocking the GR a "resetting" of the HPA axis may occur ([@b6-ndt-2-33]). Interestingly, animal work has shown that in comparison with other selective GR antagonists, mifepristone was the only compound to increase GR binding in the frontal cortex, although an increase in MR binding was also observed ([@b2-ndt-2-33]). In the neocortex, however, mifepristone selectively decreased MR binding.

GR integrity has consistently been shown to be lowered in patients with severe psychiatric disorders both functionally, using the DST ([@b68-ndt-2-33]), and structurally, with reduced GR mRNA expression in postmortem brain tissue samples ([@b81-ndt-2-33]). There is some evidence, however, that MR function may be normal or even enhanced in mood disorders ([@b85-ndt-2-33]). Although speculative, some of the therapeutic actions of mifepristone may operate through the ability of the drug to modulate corticosteroid receptor balance (ie, exposing brain MR to the elevated cortisol levels caused by GR blockade). This may be particularly so for neurocognitive functioning, which depends on the relative ratio of corticosteroid receptor occupancy ([@b45-ndt-2-33]).

Transport of cortisol into the brain
------------------------------------

Recent work has shown that many antidepressant drugs have actions on blood-brain barrier steroid transporters (such as multidrug resistance p-glycoprotein). Plasma cortisol cannot freely enter the brain by passive diffusion because its access is limited by such membrane steroid transporters which actively expel cortisol from the brain. It has been suggested that some antidepressants may inhibit membrane steroid transporters at the blood--brain barrier and in neurones, so that more cortisol is able to enter the brain ([@b58-ndt-2-33]; [@b59-ndt-2-33]), thereby restoring glucocorticoid-mediated negative feedback of the HPA axis ([@b59-ndt-2-33]). Hypercortisolemia is therefore argued to be a possible compensatory adaptive response to a central *hypo*cortisolemic state ([@b57-ndt-2-33]). Considering mifepristone: the antagonist action of mifepristone on GR causes a robust (2- to 3-fold) elevation in cortisol levels and this may facilitate HPA axis negative feedback. Certainly, this may be the case when mifepristone is administered adjunctively with other antidepressant medications (see above). This mechanism may underlie some of the clinical benefits of the drug.

Speed of response
-----------------

One notable characteristic of antiglucocorticoid strategies in studies to date is that they appear to initiate a rapid, short-term clinical response. The study of the ORG 34517 by Høyberg and colleagues in medication-free patients with major depression showed that differences between treatment arms emerged after day 7 of the trial, with significant benefits being observed at day 10--14. This was especially pronounced in patients with clearly defined HPA axis abnormalities. After this time, response rates were approximately equivalent ([@b31-ndt-2-33]). Rapid responses have also been observed following mifepristone administration in psychotic depression ([@b5-ndt-2-33]; [@b6-ndt-2-33]; [@b73-ndt-2-33]).

Alternative antiglucocorticoid strategies such as cortisol synthesis inhibition similarly alter the course of clinical response. Jahn and colleagues administered metyrapone or placebo to 63 (psychotropic) medication-free patients with major depression. A higher proportion of patients receiving metyrapone showed a positive treatment response, but importantly the response began within a week of initiation of treatment, suggesting an earlier onset of action ([@b33-ndt-2-33]).

The ability of such drugs to rapidly improve treatment response suggests that they may be used either to increase efficacy of treatment regimens in medicated patients or initiate a response that can be maintained with conventional treatments. The optimum strategy for the clinical application of GR antagonists has yet to be established, with their potential role as either first-line or adjunctive treatments being unclear.

Effects on neurocognitive function
----------------------------------

Although few studies to date have examined the neuro-cognitive effects, mifepristone may be efficacious in this respect in mood disorder.

In a recent study in rats, mifepristone was the only GR antagonist examined to increase both MR and GR binding in the frontal cortex ([@b2-ndt-2-33]). This may underpin the selective pattern of improvement in neuro-cognitive function seen in our study ([@b83-ndt-2-33]), which was restricted to tests that have been shown to be sensitive to frontal lobe dysfunction. Oitzl and colleagues have shown that mifepristone (RU-38486) injected locally into the dorsal hippocampus dose-dependently improved the performance of male Wistar rats in the water maze 24 hours after treatment ([@b53-ndt-2-33]). Importantly, opposing effects on spatial memory have been shown to occur after either phasic or continuous blockade of brain GR by intracerebroventricular administration of mifepristone. Phasic blockade was found to dose-dependently impair spatial memory (Morris water maze), examined after a daily pretraining administration, whereas continuous GR blockade resulted in a long-lasting facilitation of spatial performance ([@b54-ndt-2-33]). In humans, aspects of spatial memory are affected in various degrees in patients with hippocampal lesions ([@b35-ndt-2-33]), some tasks such as (spatial) working memory being more dependent on the integrity of the frontal lobes ([@b56-ndt-2-33]; [@b55-ndt-2-33]; [@b36-ndt-2-33]; [@b35-ndt-2-33]). Consequently, the effects of mifepristone on corticosteroid receptor expression may explain the observed pattern of neurocognitive improvement observed in studies to date.

Neuroprotection
---------------

The potential neuroprotective actions of mifepristone have been demonstrated preclinically. Mifepristone was found to protect rat primary hippocampal neurons, clonal mouse hippocampal cells, and organotypic hippocampal slice cultures against oxidative stress-induced neuronal cell death induced by amyloid beta protein, hydrogen peroxide, and glutamate ([@b3-ndt-2-33]). Interestingly, this effect was independent of the presence and activation of glucocorticoid or progesterone receptors. Other studies have also subsequently demonstrated neuroprotective effects of mifepristone ([@b25-ndt-2-33]), although the precise mechanism through which these actions are exerted is unclear. Nevertheless, these actions may be of therapeutic benefit.

Conclusions and future directions
=================================

The use of mifepristone and other GR antagonists in the treatment of mood disorders and psychosis is very much at the proof-of-concept stage. Results are encouraging and several larger-scale clinical trials are underway to better establish the clinical utility of this class of drug. Drugs targeting other facets of the HPA axis, such as CRH-1-receptor antagonists and vasopressin-1b-receptor antagonists, are also being examined ([@b86-ndt-2-33]; [@b30-ndt-2-33]; [@b40-ndt-2-33]), as well as the application of GR antagonists in the treatment of mood symptoms and cognitive impairment in neurological disorders such as Alzheimer's disease ([@b62-ndt-2-33]). Several important questions remain to be answered, including how long the treatment effects persist and the optimal method of administration, ie, continuous or repeated, short-term administrations. These data will provide valuable information on the overall efficacy and safety of this class of treatment (see [@b46-ndt-2-33]) and may ultimately lead to the development of specific antiglucocorticoid compounds for use in severe psychiatric illness.

###### 

Studies of glucocorticoid receptor antagonists in mood disorders and psychosis (see text for further details)

  Study               Drug                               Dose                                                Study design                                            N     Patient group                          Concomitant medications                                                    Effects on symptoms                                                                                                                                                                                                                                    Effects on neurocognitive function
  ------------------- ---------------------------------- --------------------------------------------------- ------------------------------------------------------- ----- -------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------
  ([@b37-ndt-2-33])   Mifepristone                       10 mg/kg single dose                                [a](#tfn1-ndt-2-33){ref-type="table-fn"} Experimental   8     MDD                                    Drug-free (2 weeks)                                                        n/a                                                                                                                                                                                                                                                    n/a
  ([@b39-ndt-2-33])   Mifepristone                       400 mg single dose                                  [a](#tfn1-ndt-2-33){ref-type="table-fn"} Experimental   7     MDD                                    Drug-free (1 week)                                                         n/a                                                                                                                                                                                                                                                    n/a
  ([@b51-ndt-2-33])   Mifepristone                       200 mg/day, up to 8 weeks                           Open-label                                              4     MDD                                    Drug-free; benzodiazepines and acetaminophen permitted                     HDRS scores decreased between 16% and 66% for all patients.                                                                                                                                                                                            n/a
  ([@b31-ndt-2-33])   ORG34517                           150-- 300 mg/day, 450-- 600 mg/day, up to 4 weeks   Double-blind, randomized, paroxetine controlled         142   MDD                                    Drug-free; benzodiazepines permitted                                       All groups improved. Larger improvement from baseline in low- dose ORG group at day 10. Patients reaching full remission significantly higher in low- than both the high-dose and paroxetine-treated groups (39.1% vs 20.5% and 31.0% respectively).   n/a
  ([@b5-ndt-2-33])    Mifepristone                       600 mg/day, 4 days                                  Double-blind, placebo controlled, crossover             5     Psychotic MDD                          Antipsychotic free (3 days); benzodiazepines and acetaminophen permitted   HDRS scores declined during mifepristone treatment in all patients. BPRS scores declined in 4 of 5 patients.                                                                                                                                           n/a
  ([@b6-ndt-2-33])    Mifepristone 1200 mg/day, 7 days   50, 600,                                            Open-label                                              30    Psychotic MDD                          Stable for 1 week prior                                                    HDRS response by dose in 2/11 (18.2%) 5/10, (50%), 3/9 (33%) patients respectively. BPRS response in 4/11 (36.4%), 7/10 (70%), 6/9 (66.7%) respectively.                                                                                               n/a
  ([@b73-ndt-2-33])   Mifepristone                       200 mg tid, 6 days                                  Open-label                                              20    Psychotic MDD                          Drug-free (1 week) except for lorazepam                                    CGI and HDRS improved after week 1, and between week 1 to 4. BPRS improved after week 4                                                                                                                                                                n/a
  ([@b83-ndt-2-33])   Mifepristone                       600 mg/day, 7 days                                  Double-blind, placebo controlled RCT                    20    Bipolar disorder (depressed)           Stable for 6 weeks prior                                                   HDRS (5.1 points), MADRS (6 points), BPRS (4 points) improved from baseline at day 14 with active drug.                                                                                                                                                SWM improved 19.8% over placebo at day 21. Spatial recognition, verbal fluency improved from baseline following active drug.
  ([@b24-ndt-2-33])   Mifepristone                       600 mg/day, 7 days                                  Double-blind, placebo controlled RCT                    20    Schizophrenia (chronic, symptomatic)   Stable for 6 weeks prior                                                   No effect on BPRS or Calgary. Improvements in HDRS and MADRS in both arms of the study (nonspecific effect).                                                                                                                                           No effect

These studies examined HPA axis responses only.

**Abbreviations:** BPRS, Brief Psychiatric Rating Scale; Calgary, Calgary Depression Scale; CGI, Clinical Global Impression; HDRS, Hamilton Depression Rating Scale; HPA, hypothalamic--pituitary--adrenal; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, Major Depressive Disorder; n/a, not assessed; RCT, randomized clinical trial; SWM, Spatial Working Memory (CANTAB); tid, three times daily.
